Uncategorized Phase III study begins for AMD drop by ModernMedecine • 2012/04/18 • 0 Comments MacuCLEAR Inc. is beginning phase III studies for its lead compound, MC-1101, for the treatment of early-stage (dry) age-related macular degeneration (AMD). Full Story →